Semax for ADHD: What the Scientific Evidence Really Shows

Does Semax help with ADHD?

There is no clinical evidence that Semax treats ADHD, as no clinical trials have ever tested Semax in individuals diagnosed with ADHD. This is an important starting point, as the connection between Semax and ADHD that appears so readily in searches actually stems from a single theoretical article – not a treatment study, not a clinical trial, and not even an animal model specifically designed to mimic ADHD. Understanding the true origin and limitations of this idea is crucial for setting realistic expectations.

What is the Semax trial for ADHD that everyone is referring to?

The article that most people searching for Semax research for ADHD refer to is a theoretical 2007 paper published in the journal *Medical Hypotheses* by Shih-Jen Tsai [1]. As the journal's name suggests, this publication is specifically intended for presenting testable hypotheses and educated speculations, not original research findings. Tsai's article did not involve any patients, experiments, or new data – it was a proposal built by combining existing pieces of evidence on the known effects of Semax on dopamine and BDNF, suggesting that Semax might have therapeutic potential for ADHD.

The reasoning proceeded as follows: ADHD is linked to dopaminergic signalling impairments and BDNF function, particularly in the prefrontal cortical circuits responsible for attention and impulse control. Since Semax was already known to potentiate the effects of psychostimulants—drugs like amphetamine—on central dopamine release and to stimulate the production of BDNF in the brain, the author proposed that these same properties might make Semax useful for treating ADHD [1].

This is a reasonable scientific hypothesis worth investigating — but it is just a hypothesis. To date, it has never been tested in an actual ADHD clinical trial, in animal models specifically designed to mimic ADHD, or in any controlled study examining the effects of Semax on attention deficit symptoms.

Are there any clinical trials for Semax and ADHD?

No. A clinical trial evaluating Semax as a treatment for ADHD in children, adolescents, or adults has never been published. This needs to be stated clearly because a theoretical paper from 2007 is sometimes cited in a way that suggests clinical evidence exists when it does not.

What exists instead is a collection of discrete studies on the effects of Semax on attention-related processes in healthy animals and, to a lesser extent, healthy humans – findings that provide significant background for the hypothesis but are not the same as demonstrating that Semax actually helps individuals with clinically diagnosed ADHD.

Semax appears to affect attention and concentration in available research.

Evidence for Semax's effects on attention comes from general cognitive and behavioural studies in animals, plus some human data from healthy volunteers and stroke patients — none of which specifically modelled ADHD.

A 15-year review of Semax research summed up decades of Russian studies and specifically cited improved selective attention as one of the main cognitive benefits observed in both rodents and healthy humans under cognitive load [2]. In behavioural animal studies using active avoidance tasks, Semax accelerated learning acquisition and improved the animals' ability to adapt behaviour following environmental disturbances, findings that researchers interpreted as reflecting enhanced attentional and adaptive processing [3].

In human brain imaging, a resting-state functional MRI study revealed that Semax altered default mode network activity in the brain, specifically expanding activity in the medial prefrontal cortex – an area heavily involved in attention regulation and executive functions [4]. This is a genuinely interesting finding for anyone interested in Semax's impact on attentional brain circuits, but it was conducted on healthy volunteers, not on individuals with ADHD. It tells us something about how Semax affects a typical brain, rather than how it might affect the specific circuit disorders seen in ADHD.

When considering ADHD, Semax's effects on dopamine are primarily linked to its potential to modulate dopaminergic neurotransmission. Although research is ongoing, some studies suggest that Semax may influence dopamine levels and activity in the brain. This modulation could potentially lead to improvements in attention, focus, and impulse control, which are commonly affected in individuals with ADHD. However, it's important to note that Semax is not an approved treatment for ADHD, and its use for this condition is experimental. Further rigorous clinical trials are needed to fully understand its efficacy and safety profile in the context of ADHD.

This is evidence that gives the hypothesis of ADHD the strongest biological basis, and it is worth explaining it in detail, as it is more complex than simply stating that Semax increases dopamine.

Semax does not directly increase dopamine levels on its own. Animal studies have shown that Semax alone did not significantly alter baseline dopamine or its breakdown products in the striatum [5]. What Semax does instead is to enhance the dopamine response to stimulation. When researchers administered Semax before D-amphetamine, the combination induced a significantly higher peak in dopamine levels in the fluid surrounding brain cells than amphetamine alone, along with more pronounced increases in locomotor activity in mice [5], [6].

This pattern of enhancement, rather than direct drive, is really pertinent to ADHD because standard ADHD medications – including amphetamines and methylphenidate – work precisely by increasing dopamine availability in the brain, and impaired dopamine signalling is one of the most consistently implicated features of ADHD neurobiology. If Semax sensitizes dopamine circuits to respond more robustly, it could theoretically make the under-active dopamine system of the ADHD brain more reactive to any naturally occurring dopaminergic signalling. This remains, however, a mechanistic possibility built from pharmacological studies in healthy rodents, rather than a demonstrated clinical effect in anyone with ADHD.

What would be needed to actually know if Semax helps with ADHD?

A proper answer to this question would require a well-designed clinical trial: individuals diagnosed with ADHD according to validated diagnostic criteria, random allocation to Semax or placebo, blinded assessment using standardised ADHD symptom scales, and a sufficiently large sample size to detect meaningful differences. Nothing remotely resembling this has been carried out.

Until such research exists, the reliable and accurate stance is that Semax has a plausible theoretical rationale for ADHD based on its dopamine-enhancing and BDNF-increasing properties, but zero direct clinical evidence to confirm it actually works for the condition.

Is Semax a stimulant like Adderall?

No, Semax is not a stimulant in the pharmacological sense that Adderall is. Adderall is a combination of amphetamine salts that works by directly forcing the release of dopamine and norepinephrine from nerve endings and blocking their reuptake, flooding the space between nerve cells with these chemicals.

Semax works through a completely different mechanism. It does not directly force neurotransmitter release on its own. Instead, animal studies show that Semax itself does not significantly alter baseline dopamine levels, but rather enhances the dopamine response when another stimulus – such as amphetamine – causes release [5]. This modulatory, rather than directly releasing, action places it in a fundamentally different pharmacological category than a classic stimulant.

The broader mechanism of Semax also includes increased BDNF and NGF [7], changes in gene expression affecting inflammation and neurotransmission [8], and modulation of GABA, glycine, and glutamate receptor activity [9] – none of these mechanisms resemble the way classic ADHD stimulant drugs work. Therefore, Semax is classified in the research literature as a nootropic and neuroprotective peptide, rather than a stimulant.

Can Semax replace Adderall?

No, and this must be stated unequivocally. Semax has never been tested as a treatment for ADHD, it has no approved indication for ADHD anywhere in the world, and it has not been compared with Adderall in any clinical trial for attention or concentration outcomes.

Adderall is an FDA-approved medication backed by decades of controlled research data specifically establishing its efficacy for ADHD symptoms in specific patient populations. Semax does not have an equivalent body of evidence for this particular condition. Any individual considering discontinuing or substituting their prescribed ADHD medication with Semax would be making that decision without any clinical evidence supporting Semax's efficacy for the treated condition, and absolutely should not do so without direct guidance from their prescribing physician.

What is the actual comparison between Semax and Adderall?

The two compounds differ in almost every significant respect. Adderall induces effects within 30–60 minutes through direct, potent stimulation of dopamine and norepinephrine release, with well-characterised dose-response relationships established by extensive clinical studies.

Semax causes measurable brain changes within minutes [10], but through modulatory, neurotrophin-driven mechanisms that build gradually, rather than delivering an immediate, powerful neurotransmitter surge. Adderall carries known risks of dependence, tolerance, cardiovascular burden, and appetite suppression—all well-documented by decades of clinical use and monitoring. Semax's risk profile is far less characterised, with no addiction signals reported in available studies [11], but also without the extensive long-term human safety monitoring Adderall has undergone.

Is Semax safer than Adderall?

Based on available evidence, Semax appears to carry a lower risk of dependence and the classic stimulant side effects – appetite suppression, cardiovascular burden, tolerance – which are well-documented with Adderall. However, appearing safer in some respects is not the same as being proven generally safer, as Semax simply does not have the decades of widespread, monitored human use behind it that Adderall can boast.

The risks of Adderall are well-characterised precisely because it has been so thoroughly studied – there’s a clear understanding of what to look out for. The risks of Semax are less characterised not necessarily because they are smaller, but because there is significantly less rigorous long-term safety research. A compound with an unknown risk profile isn't automatically safer than a compound with a well-documented risk profile – it's just less understood.

What are the potential benefits of Semax compared to Adderall?

For someone specifically diagnosed with ADHD, this comparison is somewhat irrelevant, given the complete lack of clinical evidence for Semax in this condition.

From a general cognitive support perspective outside of the specific context of ADHD, Semax's theoretical benefits include a mechanism that works *with* the brain's own regulatory systems—enhancing dopamine rather than forced release, and BDNF-driven neuroplasticity—instead of bypassing them, alongside a lack of the classic stimulant side-effect profile. These are reasonable arguments for Semax for general nootropic interest, but they do not constitute evidence that Semax is an efficacious treatment for ADHD, nor a justifiable alternative to a clinically validated medication for anyone with a formal diagnosis of ADHD.

Is Semax or Selank better for ADHD?

Neither Semax nor Selank have been tested in a clinical trial for ADHD, therefore there is no direct evidence to declare either of them superior for this specific condition. What can be compared instead are their differing pharmacological profiles and how well each of their known mechanisms might correspond to the different symptom domains that make up ADHD - inattention and impulsivity on one hand, and the anxiety and emotional dysregulation often comorbid with ADHD on the other.

The profile of Semax - dopamine enhancement, BDNF increase, and effects on attention-related brain networks [4, 5] - aligns more directly with the core attention and concentration symptoms of ADHD. Selank's profile is quite different: it is primarily an anxiolytic peptide, acting through GABA receptor modulation and enkephalinase inhibition [12]. Selank's mechanism does not share the same direct link to dopaminergic and attention-related network effects that make Semax theoretically relevant for the core symptoms of ADHD.

How do the mechanisms of Semax and Selank differ regarding ADHD-relevant symptoms?

ADHD can be understood as encompassing two broad categories of difficulties: symptoms of attention, concentration and impulsivity on the one hand, and often co-occurring anxiety, emotional reactivity and stress sensitivity, which many people with ADHD also experience on the other. Semax and Selank correspond to these two categories in quite different ways.

The dopamine-boosting and BDNF-driven mechanisms of Semax [5], [7] are more theoretically consistent with the primary attentional deficits. The calming, GABA-modulating, anxiolytic mechanism of Selank [12] is more theoretically consistent with the emotional dysregulation and anxiety that often accompany ADHD, particularly in adults, rather than with the attentional deficit itself.

None of these theoretical compatibilities have been directly tested in ADHD populations. This is worth repeating, as it’s easy for a plausible-sounding mechanistic story to start being perceived as established fact if it’s not actively confronted with what’s actually been studied and what hasn’t.

Should you use Semax or Selank specifically for attention problems?

For attention and concentration specifically, the mechanism of Semax has a more direct theoretical link, given its dopamine-enhancing effects and its influence on attention networks [4], [5], whereas the mechanism of Selank is more geared towards reducing anxiety and stress, which can indirectly disrupt attention, rather than directly addressing attentional processes.

If someone's attention difficulties are primarily driven by anxiety, racing thoughts, or stress-related mental noise, the calming properties of Selank could theoretically address the pattern of disruption more directly than Semax. If the difficulty is more about an initial lack of focus, motivation, or dopaminergic drive without a strong anxious component, Semax's profile is theoretically a better fit. This is mechanistic reasoning, not from direct comparative evidence, and should be treated as such.

What does the combination of Semax and Selank offer for attention-related concerns?

The reasoning some employ for combining Semax and Selank in the context of attention and concentration concerns is that Semax might address the dopaminergic and network side of the attention equation, while Selank would address the anxiety and stress reactivity side, theoretically covering more of the symptom picture than either compound alone.

A brain imaging study of functional connectivity that analysed both peptides in the same group of healthy volunteers found that they elicited both shared and distinct effects on brain connectivity patterns involving the amygdala [13]. This supports the idea that they engage at least partially distinct neural systems, which is consistent with—though not proof of—the idea that their combination could address different aspects of a complex symptom profile, such as ADHD.

It is important to re-emphasise that this combination has never been tested in anyone with ADHD, in any controlled study, for any attention-related outcome. The reasoning here is built entirely from separate mechanistic studies of each peptide alone in non-ADHD populations, rather than from direct evidence that the combination — or either compound alone — meaningfully helps ADHD symptoms.

A reliable conclusion regarding Semax, Selank, and ADHD is that while these nootropics have shown promise in animal studies and some limited human research for cognitive enhancement and anxiety reduction, there is currently insufficient robust scientific evidence to recommend them as a treatment for ADHD in humans. Further rigorous clinical trials are needed to establish their efficacy, safety, and optimal dosage for individuals with ADHD.

The sensible conclusion is: the idea that Semax or Selank might help with ADHD is a reasonable, biologically plausible hypothesis built from actual pharmacological discoveries. Dopamine enhancement, BDNF increase, GABA modulation, and effects on brain networks related to attention are all genuinely documented properties of these peptides.

However, a plausible hypothesis is not the same as clinical evidence, and currently there is no clinical evidence that any compound treats ADHD. Any individual diagnosed with ADHD considering these peptides as an alternative or adjunct to established treatment should clearly understand that they would be using an unproven, untested approach for this particular condition, and should thoroughly discuss any such decision with their ADHD clinician, rather than making this decision independently based on mechanistic speculation.

Disclaimer

This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a suggestion to use Semax or Selank in place of established ADHD treatment. Semax and Selank remain investigational compounds in most countries, including the United States and most European countries, and are not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition, including ADHD. They are approved and clinically used in Russia and some Eastern European countries for other indications. No clinical trials have evaluated either compound as an ADHD treatment in any population. Most of the evidence presented here comes from preclinical animal studies, a small number of human studies in non-ADHD populations, and one theoretical hypothetical article. Any individual with a diagnosed case of ADHD should not alter, discontinue, or substitute prescribed treatment without consulting their healthcare provider.

References

[1] Tsai, S. J. (2007). Semax, a analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Medical Hypotheses, 68(5), 1144–1146. https://doi.org/10.1016/j.mehy.2006.07.017

[2] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745

[3] Inozemtsev, A. N., Agapitova, A. E., Bokieva, S. B., Glazova, N. Yu., Levitskaia, N. G., Kamenskiĭ, A. A., & Miasoedov, N. F. (2013). Opposite Semax influence on conditioning and functional disturbances of avoidance responses in rats. Journal of Higher Nervous Activity named after I.P. Pavlov, 63(6), 711–718. https://doi.org/10.7868/s0044467713060063

[4] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3

[5] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8

[6] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751

[7] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108

[8] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681

[9] Sharonova, I. N., Bukanova, Yu. V., Myasoedov, N. F., & Skrebitskii, V. G. (2018). Modulation of GABA- and glycine-activated ionic currents with Semax in isolated cerebral neurons. Bulletin of Experimental Biology and Medicine, 164(5), 612–616. https://doi.org/10.1007/s10517-018-4043-8

[10] Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskiĭ, A. A., Levitskaia, N. G., Shevchenko, V. P., Grivennikov, I. A., & Miasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganic Chemistry, 32(1), 64–70. https://doi.org/10.1134/s1068162006010055

Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Organic Chemistry, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885

[12] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810

Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X